pharmaceuticals

Sanofi SA (ADR) (NYSE: SNY), is approaching a growth inflection point, according to Bank of America Merrill Lynch. The sell-side firm is projecting 6-percent earnings per share growth for the pharmaceutical company.  The Analyst Analyst Graham Parry upgraded Sanofi from Neutral to Buy and...

Initial reports of a pending M&A deal involving Shire PLC (ADR) (NASDAQ: SHPG) dates back to late March, when The Wall Street Journal reported that Japan-based Takeda Pharmaceuticals was interested in the Ireland-based pharmaceutical giant. The two companies reached a merger agreement Tuesday...

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced an encouraging update on etrasimod, its drug candidate for the treatment of autoimmune diseases like ulcerative colitis. What Happened Arena Pharmaceuticals reported topline Phase 2 results from an ongoing trial of etrasimod called OASIS...

The pharmaceutical industry is lobbying to reverse part of the recent Congressional spending bill that shifted a $10-billion consumer aid burden from the federal government to manufacturers. The Bipartisan Budget Act of 2018 accelerated the closure of the Medicare Part D coverage gap from 2020 to...

Walgreens Boots Alliance Inc (NASDAQ: WBA) is in early talks to buy the remaining 74 percent of AmerisourceBergen Corp. (NYSE: ABC) that it doesn’t already own, according to the Wall Street Journal. The drugstore operator reached out to representatives weeks ago to initiate discussions, and...

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) have lost more than 10 percent over the past year, but one analyst is confident enough to call for upside to the stock. The Analyst Credit Suisse's Martin Auster initiated coverage of Alexion Pharmaceuticals' stock with an Outperform...

The case for buying shares of Eli Lilly and Co (NYSE: LLY) no longer applies, as an analysis of the company's franchise suggests investors are underappreciating the risk surrounding its biggest diabetes franchise, according to Goldman Sachs.  The Analyst Goldman Sachs' Jami Rubin...

After a turbulent 2017, Mizuho analysts now see upside potential for Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s stock. The Analyst Mizuho Securities USA's Irina Koffler upgraded Teva's stock rating from Neutral to Buy with a price target boosted from $16 to $23. The...

The Street may be too optimistic in its outlook for Gilead Sciences, Inc. (NASDAQ: GILD) — and this isn't a bullish indicator, according to Credit Suisse. The Analyst Credit Suisse's Alethia Young downgraded Gilead's stock rating from Outperform to Neutral with a price target...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) announced Thursday a plan to eliminate more than 25 percent of its worldwide workforce as part of a strategy to slash $3 billion of annual costs. The Analyst Goldman Sachs' Jami Rubin upgraded Teva's stock from Neutral to Buy with...